JP2010506918A - ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター - Google Patents

ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター Download PDF

Info

Publication number
JP2010506918A
JP2010506918A JP2009533349A JP2009533349A JP2010506918A JP 2010506918 A JP2010506918 A JP 2010506918A JP 2009533349 A JP2009533349 A JP 2009533349A JP 2009533349 A JP2009533349 A JP 2009533349A JP 2010506918 A JP2010506918 A JP 2010506918A
Authority
JP
Japan
Prior art keywords
ethyl
methyl
group
biphenyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506918A5 (OSRAM
Inventor
ビンセント ジェイ． サントーラ，
ライアン エム． ハート，
ジェイソン ビー． イバッラ，
ダグラス エム． パーク，
アルバート エス． レン，
グレーム サンプル，
ジェフリー エー． シュルツ，
ブライアン スミス，
ジェフリー スミス，
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2010506918A publication Critical patent/JP2010506918A/ja
Publication of JP2010506918A5 publication Critical patent/JP2010506918A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2009533349A 2006-10-17 2007-10-16 ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター Withdrawn JP2010506918A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85261006P 2006-10-17 2006-10-17
US93435807P 2007-06-11 2007-06-11
PCT/US2007/022086 WO2008048609A1 (en) 2006-10-17 2007-10-16 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto

Publications (2)

Publication Number Publication Date
JP2010506918A true JP2010506918A (ja) 2010-03-04
JP2010506918A5 JP2010506918A5 (OSRAM) 2010-11-25

Family

ID=39149258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533349A Withdrawn JP2010506918A (ja) 2006-10-17 2007-10-16 ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター

Country Status (16)

Country Link
US (1) US20100240653A1 (OSRAM)
EP (1) EP2074086B1 (OSRAM)
JP (1) JP2010506918A (OSRAM)
KR (1) KR20090069333A (OSRAM)
AR (1) AR063226A1 (OSRAM)
AT (1) ATE512948T1 (OSRAM)
AU (1) AU2007313180A1 (OSRAM)
CA (1) CA2665204A1 (OSRAM)
CL (1) CL2007002977A1 (OSRAM)
EA (1) EA200970386A1 (OSRAM)
IL (1) IL197892A0 (OSRAM)
MX (1) MX2009004071A (OSRAM)
PA (1) PA8750901A1 (OSRAM)
PE (1) PE20081462A1 (OSRAM)
TW (1) TW200823204A (OSRAM)
WO (1) WO2008048609A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012232978A (ja) * 2011-05-02 2012-11-29 Lab Servier ４−｛３−［ｃｉｓ−ヘキサヒドロシクロペンタ［ｃ］ピロール−２（１Ｈ）−イル］プロポキシ｝ベンズアミドとアセチルコリンエステラーゼ阻害剤との新規な組み合わせ、及びそれを含む医薬組成物
JP2016504388A (ja) * 2013-01-09 2016-02-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 認識障害の処置のためのヒスタミンｈ３受容体調節因子としてのビフェニル−エチル−ピロリジン誘導体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20100292288A1 (en) * 2007-06-08 2010-11-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2009123714A2 (en) * 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2282992A1 (en) * 2008-04-16 2011-02-16 Arena Pharmaceuticals, Inc. Processes useful for the synthesis of (r)-1-{2-ý4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl¨-ethyl}-2-methyl-pyrrolidine
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
GB201005511D0 (en) 2010-03-31 2010-05-19 Takeda Pharmaceutical Compounds and their use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2020092604A1 (en) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Deuterated pitolisant
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
CN115160584B (zh) * 2022-07-06 2024-03-22 西北工业大学 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5500427A (en) * 1992-09-14 1996-03-19 Takeda Chemical Industries, Ltd. Cyclic compounds and their use
US5541217A (en) * 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
DE19937537A1 (de) * 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
US20040044029A1 (en) * 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
MXPA06011167A (es) * 2004-04-01 2007-01-25 Eli Lilli And Company Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
US7145005B2 (en) * 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
AU2005280921B2 (en) * 2004-09-07 2011-05-19 Msd K.K. Carbamoyl-substituted spiro derivative
WO2006058649A1 (en) * 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as h3 antagonists
CN101107227B (zh) * 2005-01-19 2010-09-22 霍夫曼-拉罗奇有限公司 5-氨基吲哚衍生物
US20060188960A1 (en) * 2005-02-18 2006-08-24 Waters Stephen M Chimeric histamine H3 receptor
PL1899334T3 (pl) * 2005-06-17 2009-04-30 Janssen Pharmaceutica Nv Związki naftyrydynowe
UA96424C2 (ru) * 2005-09-16 2011-11-10 Янссен Фармацевтика Н.В. Циклопропил амины как модуляторы н3 рецепторов гистамина
BRPI0619268A2 (pt) * 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
KR20080080201A (ko) * 2005-12-21 2008-09-02 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 치환된 아닐린 유도체
MX2008011791A (es) * 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
MX2008014743A (es) * 2006-05-19 2008-12-01 Wyeth Corp N-benzoil- y n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3.
AU2007256931B2 (en) * 2006-05-30 2013-01-24 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
JP2009542673A (ja) * 2006-06-29 2009-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒスタミンｈ３−受容体関連障害の治療に有用なヒスタミンｈ３−受容体モジュレータ
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
US7648979B2 (en) * 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7557108B2 (en) * 2007-02-07 2009-07-07 Hoffmann-La Roche Inc. (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones
US7846930B2 (en) * 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
KR20100020487A (ko) * 2007-05-24 2010-02-22 와이어쓰 엘엘씨 히스타민-3 길항제로서 아자시클릴벤즈아미드 유도체
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
AP2010005202A0 (en) * 2007-09-12 2010-04-30 Wyeth Llc Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists
WO2009067406A1 (en) * 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012232978A (ja) * 2011-05-02 2012-11-29 Lab Servier ４−｛３−［ｃｉｓ−ヘキサヒドロシクロペンタ［ｃ］ピロール−２（１Ｈ）−イル］プロポキシ｝ベンズアミドとアセチルコリンエステラーゼ阻害剤との新規な組み合わせ、及びそれを含む医薬組成物
JP2016504388A (ja) * 2013-01-09 2016-02-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 認識障害の処置のためのヒスタミンｈ３受容体調節因子としてのビフェニル−エチル−ピロリジン誘導体

Also Published As

Publication number Publication date
WO2008048609A1 (en) 2008-04-24
KR20090069333A (ko) 2009-06-30
CA2665204A1 (en) 2008-04-24
AU2007313180A1 (en) 2008-04-24
IL197892A0 (en) 2009-12-24
EP2074086A1 (en) 2009-07-01
EA200970386A1 (ru) 2009-10-30
PE20081462A1 (es) 2008-10-18
TW200823204A (en) 2008-06-01
PA8750901A1 (es) 2009-03-31
CL2007002977A1 (es) 2008-06-06
MX2009004071A (es) 2009-04-28
AR063226A1 (es) 2009-01-14
US20100240653A1 (en) 2010-09-23
EP2074086B1 (en) 2011-06-15
ATE512948T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
EP2074086B1 (en) Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
JP2009542673A (ja) ヒスタミンｈ３−受容体関連障害の治療に有用なヒスタミンｈ３−受容体モジュレータ
WO2007088450A2 (en) Chromane antagonist of the h-3 receptor
JP2005255685A (ja) カンナビノイド受容体に作用する新規なピラゾール類似体
JP2008526887A (ja) カンナビノイド受容体に作用する新規なヘテロピロール類似体
AU2008319310A1 (en) Biphenyl derivatives as modulators of the histamine-H3 receptor useful for the treatment of disorders related thereto
US20100331312A1 (en) Modulators of the histamine h3 receptor useful for the treatment of disorders related thereto
US20100292288A1 (en) Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
CN101821247A (zh) 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物
EP2943473B1 (en) Biphenyl-ethyl-pyrrolidine derivatives as histamine h3 receptor modulators for the treatment of cognitive disorders
WO2007061741A2 (en) Modulators of the h3 receptor useful for the treatment of disorders related thereto
CN101528684A (zh) 适用于治疗组胺h3受体相关病症的组胺h3受体的联苯磺酰基和苯基-杂芳基磺酰基调节剂
JP3786984B2 (ja) ピペラジン誘導体
HK1253019B (en) (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propanoic acid as histamine h3 receptor modulators for the treatment of cognitive disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101008

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120209

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20120306